---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-24-000090"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:42:37.117817+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acumen Q2 net loss expands to $20.5M; Phase 2 AD trial enrollment ahead of expectations

## Summary
- Net loss $20.5M in Q2 2024 vs $11.6M in Q2 2023; R&D spending rose to $19.5M (from $9.1M) on ALTITUDE-AD costs.
- Cash, equivalents, and securities $281.4M at June 30, 2024 (down from $306.1M at Dec 31, 2023); runway into H1 2027.
- Phase 2 ALTITUDE-AD enrollment faster than expected; over 50 sites activated in U.S., Canada, U.K., EU.
- Phase 1 subcutaneous sabirnetug study dosed first subject July 2024; topline data expected Q1 2025.
- Virtual R&D Day planned Oct 2, 2024, to detail sabirnetug science and Phase 1 results.

## SEC filing metadata
- accession: 0001576885-24-000090
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000090/0001576885-24-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000090/abos-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-24-000090
- JSON: https://secwatch.observer/filing/0001576885-24-000090.json
- Plain text: https://secwatch.observer/filing/0001576885-24-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.